Molecular Medicine
mRNA Translation
How ribosomes decode mRNA — and how vaccines hijack the same machinery
mRNA translation is the ribosome-driven decoding of messenger RNA into protein. Each elongation cycle takes ~170 ms — about 6 amino acids per second — and a 1,000-residue protein finishes in 3 minutes. Therapeutic mRNA hijacks the pathway for transient antigen expression.
- Elongation rate~6 aa/sec (mammalian); 15-20 (bacterial)
- Per-codon cycle~170 ms; consumes 2 GTP
- 1,000-aa proteinFinishes in ~3 minutes
- Start codonAUG in Kozak context (gccRccAUGG)
- COVID vaccinesBNT162b2 (Pfizer), mRNA-1273 (Moderna) — Dec 2020 EUA
- Key modificationN1-methyl-pseudouridine (2023 Nobel)
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Worked example — 12 hours after the booster shot
A 32-year-old receives 30 μg of BNT162b2 in the deltoid. The needle deposits roughly 3 × 1013 capped, polyadenylated, N1-methyl-pseudouridine-modified mRNA molecules — each encoding the full SARS-CoV-2 spike with two stabilizing proline substitutions (S-2P) — packaged in ~80 nm lipid nanoparticles of ALC-0315 (ionizable lipid), ALC-0159 (PEG-lipid), DSPC, and cholesterol.
Within minutes, dendritic cells and muscle fibers at the injection site take up LNPs via endocytosis. The ionizable lipid protonates at endosomal pH 5-6, destabilizes the membrane, and dumps the mRNA payload into the cytosol. Each cell now contains thousands of free mRNAs.
Cytosolic eIF4F complexes bind the m7G cap. The 40S subunit, loaded with Met-tRNAi and initiation factors, scans 5' to 3' until it hits the AUG in good Kozak context. The 60S joins; an 80S elongating ribosome is ready. At 6 amino acids per second, the 1,273-residue spike protein takes ~210 seconds (3.5 minutes) per ribosome — but each mRNA carries 8-12 ribosomes as a polysome, so output is fast.
By hour 24 the antigen is at peak expression. The ER-localized spike (signal peptide directs it to the ER) trimerizes, is processed in the Golgi, and is displayed on the cell surface and secreted as soluble S-2P. MHC-I presents internal peptides to CD8 T cells; lymphatic drainage carries soluble antigen to draining lymph nodes for B-cell capture and germinal center reactions.
By day 7 most mRNA is degraded by XRN1 and the exosome. By day 14 the antigen is gone. The immune memory — class-switched IgG, memory B cells in germinal centers, tissue-resident memory T cells — persists for months to years.
A 60-year story — from Crick to Karikó
- 1957. Francis Crick states the central dogma: DNA → RNA → protein.
- 1961. Brenner, Jacob, Meselson show mRNA is the unstable intermediate that carries the gene message to ribosomes.
- 1966. Nirenberg and Khorana complete the genetic code — 64 codons mapped to 20 amino acids and stop signals.
- 1990. Wolff et al. inject naked mRNA into mouse muscle and detect protein expression — proof of concept for mRNA therapeutics, but stability and innate immune activation crushed enthusiasm for a decade.
- 2005. Katalin Karikó and Drew Weissman publish that pseudouridine-modified mRNA evades TLR3, TLR7, and TLR8, and translates more efficiently.
- 2012. Moderna founded; BioNTech (founded 2008) deepens mRNA-vaccine R&D.
- 2020. Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 receive FDA emergency use authorization within 11 months of the SARS-CoV-2 genome being published — the fastest vaccine development in history. Billions of doses follow.
- 2023. Karikó and Weissman receive the Nobel Prize in Physiology or Medicine.
mRNA therapeutics vs. traditional modalities
| Property | mRNA | Recombinant protein | AAV gene therapy | DNA vaccine |
|---|---|---|---|---|
| Genome integration | None (cytoplasmic) | None | Rare; mostly episomal | Possible at low rate |
| Duration of expression | Days to ~2 weeks | Hours to weeks (pharmacokinetics) | Years to lifetime | Weeks to months |
| Manufacturing speed | Days to weeks (sequence in → mRNA out) | Months (cell line stability) | Months (capsid production) | Days to weeks |
| Cost per dose | ~$10-30 (BNT162b2 wholesale) | Variable; biologics $1k-100k+ | $2M+ (Zolgensma) | Low |
| Cold chain | −70°C (BNT162b2), −20°C (mRNA-1273); now refrigerator-stable formulations | 2-8°C typical | −80°C frozen | 2-8°C |
| Repeat dosing | Standard (transient) | Standard | Limited by capsid immunity | Standard |
Why mRNA translation matters
- Pandemic preparedness. Sequence-to-vaccine in weeks, not years. BNT162b2 design was finalized days after SARS-CoV-2 genome publication.
- Personalized cancer vaccines. Patient tumor sequencing → neoantigen mRNA → infusion. Moderna mRNA-4157 + pembrolizumab cut melanoma recurrence ~44% in phase 2.
- Protein replacement. Repeated mRNA dosing for OTC deficiency, methylmalonic acidemia, propionic acidemia in trials.
- In vivo CAR-T. LNP-mRNA encoding CARs targeting heart fibroblasts (TRBV) reduces cardiac fibrosis in mice; trials underway.
- Antibiotic targets. Bacterial 70S ribosomes are the target of aminoglycosides (30S), tetracyclines (A site), macrolides (50S exit tunnel), chloramphenicol (peptidyl transferase), linezolid (initiation).
- Cancer chemotherapy. Trabectedin and homoharringtonine inhibit elongation; targeted translation-initiation inhibitors are in development.
Common misconceptions
- mRNA vaccines change your DNA. mRNA does not enter the nucleus and has no reverse transcriptase. It is degraded by cytosolic nucleases within days.
- The spike protein from a vaccine spreads forever. Spike protein is detectable for ~1-2 weeks at the injection site and draining lymph nodes; circulating levels are picograms per mL.
- One ribosome per mRNA. Polysomes carry 8-15 ribosomes per message simultaneously, multiplying output.
- All AUGs are start codons. Internal AUGs in poor Kozak context are skipped; only the first AUG in good context (typically) initiates.
- Ribosomes are protein machines. The catalytic peptidyl transferase center is rRNA — the ribosome is a ribozyme.
- Translation is uniform. Rare codons, mRNA secondary structure, and ribosome collisions create pauses that shape co-translational folding.
Frequently asked questions
How fast does the ribosome translate?
In mammalian cells the elongation rate is roughly 5-6 amino acids per second per ribosome (about 170 ms per cycle). A 1,000-residue protein finishes in roughly 3 minutes. Bacterial ribosomes run faster — about 15-20 aa/sec at 37°C. Speed is not uniform: codons with rare tRNAs slow elongation, creating pause sites that aid co-translational folding and membrane insertion. Polysomes (multiple ribosomes on one mRNA) amplify output — a heavily translated mRNA can carry 10-15 ribosomes simultaneously, so one message produces many protein copies per minute.
How is the start codon found?
Eukaryotic initiation is cap-dependent. The 40S small subunit, bound to initiator Met-tRNAi and initiation factors eIF1, eIF1A, eIF2-GTP, eIF3, eIF5, plus the eIF4F cap-binding complex (eIF4E + eIF4G + eIF4A helicase), recognizes the m7G cap at the mRNA 5' end and scans 5' to 3' until it encounters an AUG in good Kozak context (gccRccAUGG). GTP hydrolysis on eIF2 commits to that AUG, eIF5B brings the 60S subunit, and an 80S ribosome with Met-tRNAi in the P site is ready to elongate. Internal ribosome entry sites (IRES) bypass scanning under stress.
What happens at each elongation cycle?
Three steps. Decoding: the next aminoacyl-tRNA, escorted by eEF1A-GTP, samples the A-site codon; correct codon-anticodon pairing in the 28S/18S rRNA decoding center triggers GTP hydrolysis and accommodation. Peptidyl transfer: the alpha-amino group of the A-site aminoacyl-tRNA attacks the carbonyl of the P-site peptidyl-tRNA, forming a new peptide bond — this is catalyzed by 28S rRNA (the ribosome is a ribozyme). Translocation: eEF2-GTP drives the ribosome forward by one codon; the tRNAs shift P→E and A→P. Each cycle consumes 2 GTP.
How do mRNA vaccines work?
A lipid nanoparticle (~80 nm) packages capped, polyadenylated, pseudouridine-modified mRNA encoding the antigen (for COVID, the SARS-CoV-2 spike with two stabilizing proline substitutions). The LNP fuses with endosomal membranes, releasing mRNA into the cytosol where host ribosomes translate it for several days. The expressed antigen is displayed via MHC-I and shed for B-cell recognition, generating neutralizing antibodies and CD8 T cells. The mRNA is degraded by normal cellular nucleases; it never enters the nucleus and cannot integrate into genomic DNA. Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 received FDA emergency use authorization in December 2020.
Why is pseudouridine used in therapeutic mRNA?
Unmodified in vitro transcribed mRNA strongly activates pattern recognition receptors — TLR3, TLR7, TLR8, RIG-I, MDA5, PKR — triggering interferon and shutdown of translation. Karikó and Weissman showed in 2005 that replacing uridine with N1-methyl-pseudouridine evades these sensors while preserving (in fact enhancing) translation. The Pfizer and Moderna vaccines use 100% N1-methyl-pseudouridine. This work won the 2023 Nobel Prize in Physiology or Medicine. Additional engineering: optimized cap (cap1 analogs like CleanCap), 5' and 3' UTRs from highly stable transcripts (alpha-globin), GC-enriched codon optimization, and a 100-120 nt poly-A tail.
What other therapeutic mRNA programs exist?
mRNA cancer vaccines: BioNTech and Moderna are running personalized neoantigen vaccines — tumor sequencing identifies patient-specific mutations, mRNA encoding those peptides is manufactured and infused with anti-PD1, with phase 2 melanoma data showing reduced recurrence. Infectious disease: RSV (Moderna mRESVIA approved 2024), CMV, influenza, HIV mRNA candidates in trials. Protein replacement: mRNA encoding propionyl-CoA carboxylase, OTC, phenylalanine hydroxylase for metabolic diseases. Regenerative medicine: VEGF mRNA injected into ischemic myocardium. CAR-T from mRNA (transient, safer): mRNA-encoded CARs avoid permanent T-cell modification.
How long does therapeutic mRNA last?
Pharmacokinetics in the LNP era. After IM injection, lipid nanoparticles deposit at the injection site and drain to lymph nodes; ~10% of measured protein expression sits in liver hepatocytes after IV delivery. Translation peaks at 24-48 hours and declines as mRNA is degraded by host nucleases — most mRNA is cleared within 5-7 days. Translated protein (e.g. spike) is detectable for 1-2 weeks. This transience is a safety feature — unlike viral vector gene therapy, mRNA expression self-limits and does not modify the genome. For chronic protein replacement, repeated dosing is required.